Plain-English translation of NCT07275697 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
The WAIT study is testing whether semaglutide (a once-weekly injection used for weight loss) can improve the success of catheter ablation—a procedure that treats irregular heartbeats caused by atrial fibrillation. Researchers believe that losing weight before this procedure might help keep your heart rhythm stable longer after surgery and reduce symptoms.
Extra weight is linked to heart rhythm problems and makes ablation surgery less likely to work long-term. While weight loss is recommended before this procedure, it's hard for most people to achieve through diet and exercise alone. This trial is testing whether this medication could help patients lose meaningful weight before surgery and ultimately improve their outcomes.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will be randomly assigned to either receive the weekly injection plus standard care, or standard care alone. The active treatment group will receive the medication starting at a low dose and gradually increasing over time, for at least three months before your scheduled ablation surgery. All participants will have a small monitor implanted after surgery to track your heart rhythm for one year. You'll attend routine clinical visits and have your weight, blood pressure, and other health markers checked as part of normal care.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
Sweden